Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

22.000
-0.340-1.52%
Volume:2.12M
Turnover:47.51M
Market Cap:19.18B
PE:42.31
High:23.000
Open:22.340
Low:21.940
Close:22.340
52wk High:26.000
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:1.66
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.520
ROE:1.46%
ROA:-1.24%
PB:1.94
PE(LYR):42.31
PS:4.45

Loading ...

Hutchmed (China) - Net Income Attributable to Hutchmed at $15.90 Mln in H1 2026

THOMSON REUTERS
·
Jul 30

Hutchmed China Ltd - Hutchmed Reports 2026 Interim Results

THOMSON REUTERS
·
Jul 30

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

GlobeNewswire
·
Jul 07

Hutchmed Gets China Nod for Gastric Cancer Drug Application

MT Newswires Live
·
Jul 02

HUTCHMED's Savolitinib Gains Conditional NMPA Approval for MET-Amplified Gastric Cancer

Stock News
·
Jul 02

Hutchmed Says China Regulator Grants Conditional Approval for Orpathys in Met-amplified Gastric Cancer

Reuters
·
Jul 02

Hutchmed Announces Nmpa Approval for Orpathys® for the Treatment of Gastric Cancer Patients with Met Amplification

THOMSON REUTERS
·
Jul 02

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

GlobeNewswire
·
Jul 02

HUTCHMED Sets 30 July Board Meeting to Approve 2026 Interim Results; Webcast Details Announced

Bulletin Express
·
Jun 30

Hutchmed Schedules Webcast Presentation Following Interim Results Announcement

Reuters
·
Jun 30

Hutchmed China Ltd - Hutchmed to Announce 2026 Half-year Results

THOMSON REUTERS
·
Jun 30

Hutchmed to Announce 2026 Half-year Financial Results

THOMSON REUTERS
·
Jun 30

HUTCHMED to Announce 2026 Half-Year Financial Results

GlobeNewswire
·
Jun 30

Hutchmed Says Phase II Fanregratinib Trial in Fgfr2-altered Bile Duct Cancer Posts 42.5% Response Rate

Reuters
·
Jun 25

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

GlobeNewswire
·
Jun 25

Hutchmed Unveils Phase III Data for Sovleplenib in wAIHA at 2026 EHA Congress

Stock News
·
Jun 12

HUTCHMED’s sovleplenib delivers 66% durable hemoglobin response in Phase III warm AIHA trial; China NDA under priority review

Bulletin Express
·
Jun 12

HUTCHMED says China regulator accepts sovleplenib NDA for wAIHA, grants priority review

Reuters
·
Jun 12

HUTCHMED says Phase III ESLIM-02 trial shows sovleplenib lifts durable response in warm autoimmune hemolytic anemia

Reuters
·
Jun 12

HUTCHMED files for AIM block admission of 43.62 million shares linked to 2026 option plan

Bulletin Express
·
Jun 05